By IgeaHub
MERCK, KNOWN AS MSD OUTSIDE THE UNITED STATES AND CANADA, OFFERS HEALTH SOLUTIONS THROUGH ITS PRESCRIPTION MEDICINES, VACCINES, BIOLOGIC THERAPIES AND ANIMAL HEALTH PRODUCTS.
The company runs its operations through four operating segments, the Pharmaceutical, Animal Health, Alliances and Healthcare Services segments. The company recorded sales of USD 39.5 billion, a decrease by 6.5% compared to a decrease of 4.1% in 2014. This can be attributed to the impact of acquisitions of Cubist Pharmaceuticals, Inc. in 2015, the divestiture of Merck’s Consumer Care business (MCC) in 2014 along with the product divestitures and the termination in 2014 of the Company’s relationship with AstraZeneca LP. Furthermore, the unfavorable effect from foreign exchange also contributed to the declined growth. The earnings per share in 2015 was USD 1.58. The total pharmaceuticals sales in 2015 was USD 34.8 billion accounting for 88.0% of the total sales. The pharmaceutical sales of the company in 2015 declined by 3.5% from 2014, due to decreased sales of HCV drugs – PegIntron, Victrelis; inflammatory disease drug – Remicade; pneumococcal vaccine – Pneumovax 23, respiratory drugs – Nasonex; and cardiovascular drug – Vytorin. Moreover increased competition by generic and biosimilar products also resulted in declined sales.
In 2016, Merck stood at USD 29.7 billion, total increase of 1.4%, as compared to 2015 fiscal nine months sales of $29.3 billion. The fiscal third quarter (Q3) sales were USD 10.5 billion an increase of 4.6% compared to 2015 Q3 sales with earnings per share at USD 0.79. The company recorded a total pharmaceutical sales of fiscal nine months at USD 26.2 billion in 2016 which is 1.9% higher as compared to the same period in 2015, mainly due to pharmaceutical and animal health products growth, and products acquired in acquisition of Cubist. Q3 pharmaceutical sales stood at USD 9.4 billion an increase of 5.8% as compared to the same period a year ago. Contributors to the growth were strong sales of vaccines – Gardasil (Human Papillomavirus), Pneumovax 23 (pneumococcal) and ProQuad (Measles, Mumps, Rubella and Varicella Virus Vaccine Live); oncology drugs – Keytruda; hepatitis drug – Zepatier; neuromuscular drugs – Bridion; respiratory drugs – Singulair; and cardiovascular drugs – Zetia.
Comentários